In yesterday’s Wall Street session, TG Therapeutics Inc. (NASDAQ:TGTX) shares traded at $11.29, up 2.17% from the previous session.
9 analysts cover TG Therapeutics Inc. (NASDAQ:TGTX), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $41.00 and a low of $6.00, we find $32.00. Given the previous closing price of $11.05, this indicates a potential upside of 189.59 percent. TGTX stock price is now -30.32% away from the 50-day moving average and -35.72% away from the 200-day moving average. The market capitalization of the company currently stands at $1.68B.
The stock has received a hold rating from 1 analysts and a buy rating from 7. Brokers who have rated the stock have averaged $28.94 as their price target over the next twelve months.
With the price target reduced from $16 to $12, Goldman Upgraded its rating from Sell to Neutral for TG Therapeutics Inc. (NASDAQ: TGTX).
In other news, WEISS MICHAEL S, CEO and President bought 100,000 shares of the company’s stock on Aug 11. The stock was bought for $1,013,000 at an average price of $10.13. Upon completion of the transaction, the CEO and President now directly owns 12,073,021 shares in the company, valued at $136.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23, Director Lonial Sagar sold 34,854 shares of the business’s stock. A total of $814,538 was realized by selling the stock at an average price of $23.37. This leaves the insider owning 93,878 shares of the company worth $1.06 million. Insiders disposed of 138,501 shares of company stock worth roughly $1.56 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TGTX stock. A new stake in TG Therapeutics Inc. shares was purchased by HOLOCENE ADVISORS, LP during the first quarter worth $18,353,000. RENAISSANCE TECHNOLOGIES LLC invested $6,054,000 in shares of TGTX during the first quarter. In the first quarter, CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in TG Therapeutics Inc. valued at approximately $3,699,000. CLEAR STREET LLC acquired a new stake in TGTX for approximately $3,614,000. OSSIAM purchased a new stake in TGTX valued at around $3,153,000 in the second quarter.
On Thursday morning TG Therapeutics Inc. (NASDAQ: TGTX) stock kicked off with the opening price of $10.92. During the past 12 months, TG Therapeutics Inc. has had a low of $4.86 and a high of $35.67. As of last week, the company has a debt-to-equity ratio of 2.41, a current ratio of 2.90, and a quick ratio of 2.50. The fifty day moving average price for TGTX is $15.97 and a two-hundred day moving average price translates $17.58 for the stock.
The latest earnings results from TG Therapeutics Inc. (NASDAQ: TGTX) was released for Jun, 2023. The company reported revenue of $16.07 million for the quarter, compared to $0.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2606.06 percent.
TG Therapeutics Inc.(TGTX) Company Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
